Phase 2 trial results presented at ASCO showed responses to anti–PD-1 antibody pembrolizumab (Keytruda) in about 60% of colorectal cancers with MMR deficiency, but no responses in CRC lacking this feature. Link is below for those interested. Exciting result for that small subset of patients, which is only 4% of metastatic CRC. SIRT unlikely to be replaced by this expensive new therapy, I don't see why they couldn't be used together in the MMR deficient group.
http://www.ascopost.com/ViewNews.aspx?nid=27670
Immunotherapy, page-4
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $56.24M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.5¢ | 13.0¢ | $109.3K | 836.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 365703 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 812922 | 5 |
View Market Depth
| Last trade - 15.53pm 28/06/2024 (20 minute delay) ? |
| SRX (ASX) Chart |